Free Trial

Century Therapeutics Q1 2024 Earnings Report

Century Therapeutics logo
$0.44 -0.02 (-4.34%)
As of 04/4/2025 04:00 PM Eastern

Century Therapeutics EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Century Therapeutics Revenue Results

Actual Revenue
$0.86 million
Expected Revenue
$0.30 million
Beat/Miss
Beat by +$560.00 thousand
YoY Revenue Growth
N/A

Century Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Remove Ads

Century Therapeutics Earnings Headlines

This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Brokers Set Expectations for IPSC FY2025 Earnings
See More Century Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email.

About Century Therapeutics

Century Therapeutics (NASDAQ:IPSC), a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

View Century Therapeutics Profile

More Earnings Resources from MarketBeat